Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02544607

Organisation Name: Massachusetts General Hospital

Overal Status: Completed

Start Date: March 2016

Last Update: April 16, 2019

Lead Sponsor: Massachusetts General Hospital

Brief Summary: Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.

Conditions:
  • Depression
  • Anxious Depression
  • Major Depressive Disorder


Total execution time in seconds: 0.19559097290039